Melanoma vaccine: a real breakthrough, and a business too

Melanoma vaccine: it treats the tumor, it does not prevent it, and doubts remain

A patient who had surgery for a malignant melanoma on his back remembers his dermatologist repeatedly telling him how lucky he had been. Five years later, survival is almost taken for granted. That is the reality that gives meaning to the August 21 announcement: the first vaccine against melanoma, the most aggressive form of skin cancer, does not prevent the tumor, it treats it.

Oncologist Karmele Mujika, from Osakidetza (the Basque public health service), explained that the vaccine generates an immune response and seeks to prevent relapses in patients whose tumor has already been removed. No primary prevention: it is a personalized therapy for those who have already been through the operating room. And that is where the nuances begin.

A treatment, not a prevention

It is not a vaccine like the ones that prevent infection before it happens. It is a boost to the immune system to stop residual tumor cells from reappearing. The distinction is not merely semantic: it determines who the vaccine is intended for and with what expectations. Healthy people have nothing to get injected with.

The enthusiasm is understandable, but specialists point out the gaps: long-term side effects and overall survival data are unknown. Personalized medicine, yes; complete evidence, no.

The business of hope

The market reaction was immediate: Moderna shares rose 150% after the announcement. No one doubts that the breakthrough may save lives. But the equation between medicine and business is not new, and the mRNA precedent has left scars.

The patient's perspective

Those who have been through a melanoma see it differently. One patient says that if the tumor had been at an advanced stage, he would have accepted the vaccine without hesitation. The word cancer is frightening. Early detection remains the difference between a scare and a years-long struggle.

While waiting for the survival data that will confirm the real benefit, the news is hopeful, with fine print. While oncologists call for caution, the market has already voted. The breakthrough is scientific. The business is too.